GHRS

GH Research PLC

6.00 USD

Last updated Dec 10, 21:19 UTC

Yesterday HIGH

$6.09

Yesterday LOW

$5.91

52w HIGH

$14.64

52w LOW

$5.7

EPS

-0.11

PE

-54.55

Next Earnings

Feb 29, 2024

Overview News Government Trades

GH Research PLC stock is down -26.92% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.

GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD)

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

ghres.com

Lara Goldstein

Tue Sep 5, 2023

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Lara Goldstein

Mon Aug 28, 2023

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Lara Goldstein

Thu Aug 24, 2023

GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharma company developing novel mebufotenin (5-MeO-DMT) therapies for Treatment-Resistant Depression (TRD) and one of the highest trading psychedelics stocks listed in Nasdaq, shared its financial results and business updates for its second quarter en
Benzinga Newsdesk

Wed Aug 23, 2023

GH Research Q2 EPS $(0.15) Down From $(0.01) YoY, Cash Balance of $238.1M Sufficient to Fund Operating Expenses, Capital Expenditure into 2026

GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.15) per share. This is a 2400 percent decrease over losses of $(0.01) per share from the same period last year.
Lara Goldstein

Mon Aug 21, 2023

Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports

Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds
Lara Goldstein

Mon Aug 14, 2023

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Lara Goldstein

Thu Aug 3, 2023

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances with that of classic drugs.
Lara Goldstein

Fri Jul 28, 2023

Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial

UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:
Benzinga Newsdesk

Thu Jul 6, 2023

HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $45 Price Target

HC Wainwright & Co. analyst Patrick Trucchio reiterates GH Research (NASDAQ:GHRS) with a Buy and maintains $45 price target.
Lara Goldstein

Mon May 15, 2023

Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More

Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths Ph.D. Professorship Fund.